Eiger Biopharmaceuticals
Eiger Biopharmaceuticals is committed to bringing to market novel products for the treatment of rare diseases.
The US-based company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed.
Latest Eiger Biopharmaceuticals News & Features
14 September 2023
6 October 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze